AavantiBio Inc

AavantiBio Inc. is a gene therapy company based in Cambridge, Massachusetts. The company currently employs 15 people. AavantiBio's platform is dedicated to developing innovative gene therapies for rare diseases. AavantiBio focuses on advancing gene therapies for areas of high unmet medical need, with a lead program targeting Friedreich's Ataxia, a rare inherited genetic disease affecting the heart and central nervous system. The company collaborates with the University of Florida's Powell Gene Therapy Center and the MDA Care Center at UF Health. AavantiBio benefits from strategic partnerships with these renowned research institutions, allowing them to leverage the expertise of co-founders Barry Byrne, M.D., Ph.D., and Manuela Corti, P.T., Ph.D., who are both leading gene therapy researchers. For more information about AavantiBio and its commitment to developing novel treatments for rare diseases, please visit their website at aavantibio.com.